Elidel: Advanced Topical Treatment for Atopic Dermatitis Relief
Elidel
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | 58.50 $ | 58.50 $ (0%) | 🛒 Add to cart |
| 2 | 52.65 $ | 117.00 $ 105.30 $ (10%) | 🛒 Add to cart |
| 3 | 46.80 $ | 175.50 $ 140.40 $ (20%) | 🛒 Add to cart |
| 4 | 43.88 $ | 234.00 $ 175.50 $ (25%) | 🛒 Add to cart |
| 5 | 39.78 $ | 292.50 $ 198.90 $ (32%) | 🛒 Add to cart |
| 6 | 35.10 $ | 351.00 $ 210.60 $ (40%) | 🛒 Add to cart |
| 7 | 31.76 $ | 409.50 $ 222.30 $ (46%) | 🛒 Add to cart |
| 8 | 29.25 $ | 468.00 $ 234.00 $ (50%) | 🛒 Add to cart |
| 9 | 27.30 $ | 526.50 $ 245.70 $ (53%) | 🛒 Add to cart |
| 10 | 25.74 $
Best per tube | 585.00 $ 257.40 $ (56%) | 🛒 Add to cart |
Synonyms | |||
Elidel (pimecrolimus) cream 1% is a non-steroidal topical immunomodulator specifically formulated for the management of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients aged 2 years and older. It works by selectively inhibiting T-cell activation and the release of inflammatory cytokines, providing targeted control of the underlying immunological processes driving eczema flare-ups. This prescription medication offers a valuable alternative to corticosteroids, particularly for sensitive skin areas and long-term intermittent use, with a well-established safety profile demonstrated in clinical trials spanning over two decades.
Features
- Contains pimecrolimus 10 mg/g (1%) as the active pharmaceutical ingredient
- White, homogeneous cream formulation for easy application and absorption
- Available in 30g, 60g, and 100g tubes with precise dosing recommendations
- Non-greasy, fragrance-free base suitable for sensitive skin
- Specifically designed for cutaneous use only; not for ophthalmic, oral, or intravaginal use
- Manufactured under strict pharmaceutical quality control standards
- Stable at room temperature with a defined shelf life
Benefits
- Provides rapid relief from itching, redness, and inflammation associated with eczema
- Reduces frequency and severity of atopic dermatitis flare-ups with consistent use
- Suitable for sensitive skin areas including face, neck, and skin folds where steroids may be problematic
- Non-steroidal mechanism avoids corticosteroid-related side effects such as skin thinning
- Allows for long-term management with intermittent application as needed
- Minimal systemic absorption when used as directed in appropriate patient populations
Common use
Elidel cream is primarily indicated for the short-term and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients 2 years of age and older who may not adequately respond to or may develop side effects with conventional treatments. It is particularly valuable for treating delicate skin areas including the face, eyelids, neck, and intertriginous areas where topical corticosteroids may produce unwanted effects. Clinical studies demonstrate effectiveness in reducing the signs and symptoms of eczema, including pruritus, erythema, and induration/papulation.
Dosage and direction
Apply a thin layer of Elidel cream twice daily to affected skin areas. Gently rub in the cream until it disappears. Use the smallest amount needed to control signs and symptoms. Treatment should begin at the first signs of atopic dermatitis symptoms. Continue application until complete clearance of signs and symptoms. If signs and symptoms persist beyond 6 weeks, re-evaluation of the diagnosis is recommended. For long-term management, apply at the first signs of recurrence to prevent full flare-up. Wash hands after application unless hands are being treated.
Precautions
Avoid exposure to natural or artificial sunlight (including tanning beds) during treatment. Appropriate sun protection measures including clothing and broad-spectrum sunscreen should be used. Not recommended for use under occlusive dressings. Use should be limited to affected areas. Not for use in patients with Netherton’s syndrome or other skin conditions where skin barrier may be compromised. Monitor patients for skin infections during treatment. Discontinue if varicella zoster virus, herpes simplex virus, or eczema herpeticum infections develop. Use in children under 2 years of age is not recommended.
Contraindications
Hypersensitivity to pimecrolimus or any component of the formulation. Patients with active cutaneous viral infections (e.g., herpes simplex, varicella zoster). Patients with congenital or acquired immunodeficiencies. Not for use in patients with malignant or pre-malignant skin conditions. Contraindicated in patients with a history of lymphoproliferative disorders. Not recommended during pregnancy unless clearly needed. Should not be used by nursing mothers unless potential benefit justifies potential risk to infant.
Possible side effects
Most common side effects include application site burning (26%), headache (6.5%), and nasopharyngitis (6.2%). Other reported reactions include cough (3.3%), fever (2.6%), and influenza-like symptoms (2.1%). Less frequently observed effects include skin infections, folliculitis, herpes simplex, varicella, and molluscum contagiosum. Rare cases of lymphadenopathy have been reported. Most local reactions are mild to moderate and typically diminish after the first few days of treatment. Systemic absorption is minimal with appropriate use.
Drug interaction
Formal drug interaction studies have not been conducted with topical pimecrolimus. Theoretical interactions with drugs that inhibit CYP3A metabolism should be considered. Concurrent use with other topical preparations, especially corticosteroids, may increase systemic absorption. Avoid concomitant use with other immunosuppressive agents. Use with caution in patients receiving phototherapy. No clinically significant interactions with vaccines have been observed, though clinical experience remains limited.
Missed dose
If a dose is missed, apply as soon as remembered unless it is almost time for the next scheduled application. Do not double the dose to make up for a missed application. Resume regular dosing schedule. Consistent application is important for optimal therapeutic effect, particularly during acute flare-up management.
Overdose
Topical overdose is unlikely due to minimal systemic absorption. However, excessive application may increase the risk of systemic exposure and adverse effects. If accidental ingestion occurs, seek medical attention immediately. Symptoms of overdose might include gastrointestinal distress, headache, and potential immunosuppressive effects. Supportive care should be provided as needed. There is no specific antidote for pimecrolimus overdose.
Storage
Store at room temperature between 15°C and 30°C (59°F and 86°F). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any medication that has changed color or consistency.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Individual response to medication may vary. Use only as directed by prescribing physician. Report any adverse reactions to your healthcare provider immediately.
Reviews
Clinical studies involving over 20,000 patients demonstrate Elidel’s efficacy and safety profile. In randomized controlled trials, 51-61% of patients achieved clear or almost clear skin after 6 weeks of treatment. Pediatric studies show similar efficacy with 54.5% of children achieving treatment success. Long-term studies (up to 4 years) confirm maintained efficacy with intermittent use. Patient satisfaction surveys indicate high rates of improvement in quality of life measures, particularly regarding sleep improvement and reduction of itching. Dermatologists consistently report favorable outcomes in appropriate patient populations.